Home

Membranous glomerulonephritis treatment guidelines

The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis shed light on the complex world of glomerulonephritis therapy. However, they may no longer apply to idiopathic membranous nephropathy, as recently concluded by the KDIGO 2019 Working Group. In adults with biopsy-proven idiopathic membranous nephropathy, what immunosuppressive agents compared to placebo no treatment or other immunosuppressive therapies improve efficacy outcomes (all-cause mortality, end-stage kidney disease, ≥50% loss of GFR, annual loss of GFR, complet In hepatitis-associated membranous nephropathy, antivirals may be useful. Symptomatic treatment includes the following: A low-salt diet is key to reducing anasarca. Protein restrictions may or may.. The KDIGO 2012 recommendations for treatment of idiopathic membranous nephropathy in adults and the 2019 MENTOR-based shift of paradigm. (A) The KDIGO 2012 recommendations for treatment of idiopathic membranous nephropathy [].Two alternative immunosuppressive regimens are proposed if there is no initial response to antiproteinuric therapy for 6 months In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A 2 receptor (PLA2R) and thrombospondin type-1

General supportive measures in all patients with MN include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, treatment of dyslipidemia, and, in select patients, anticoagulation Because of poor performance of cyclosporin, the MENTOR study suggests that rituximab should be the recommended alternative agent for the treatment of membranous nephropathy when alkylating agents are not suitable (e.g., in women of child-bearing age, those with increased cancer risk due to tobacco exposure, and prior cyclophosphamide)

Treatment of idiopathic membranous nephropathy in adults

The KDIGO Clinical Practice Guidelines for Glomerulonephritis recommended tacrolimus as an alternative regimen for the initial therapy for Idiopathic membranous nephropathy (IMN), however, large observational studies evaluating tacrolimus treatment in IMN remains rare Approach to treatment is based on risk (low, medium, or high) of progression of renal disease. Treatment in low-risk patients is largely conservative, including a low-sodium and low-protein diet and statins for hyperlipidaemia Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab Management and Treatment What are the treatments for membranous nephropathy (MN)? Treatment for MN depends on the type and cause. If you have primary MN and the levels of protein in your urine are not severe, your kidney function is stable and you have not had a complication of MN (such as a blood clot), your nephrologist may choose to use the following treatments without medications to.

Membranous Glomerulonephritis Treatment & Management

Dahan K. [Membranous nephropathy: Diagnosis, new insights in pathophysiology, and therapeutic approach]. Rev Med Interne. 2016 May 25. . Tran TH, J Hughes G, Greenfeld C, Pham JT. Overview of current and alternative therapies for idiopathic membranous nephropathy. Pharmacotherapy. 2015 Apr. 35 (4):396-411. Treatment of secondary membranous nephropathy is guided by the treatment of the original disease. For treatment of idiopathic membranous nephropathy, the treatment options include immunosuppressive drugs and non-specific anti-proteinuric measures such as ACE inhibitors or angiotensin II receptor blockers It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy

Minimal change nephrotic syndrome

Membranous nephropathy (MEM-bruh-nus nuh-FROP-uh-thee) occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria). For many, loss of these proteins eventually causes signs and symptoms. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal Related articles in PubMed Yoga therapy for Obsessive Compulsive Disorder (OCD): A case series from India

Membranous nephropathy (MN) is a common cause of adult nephrotic syndrome and is seen less commonly in children. The field has advanced significantly and rapidly in the past decade, with the introduction of new tools to diagnose, classify, and monitor disease activity. This Core Curriculum is intended to update the reader on the recent progress. Idiopathic Membranous Nephropathy (IMN) Evaluation of MN. Perform appropriate investigations to exclude secondary causes in all cases of biopsy-proven membranous nephropathy. (Not Graded) Selection of Adult Patients with IMN to Be Considered for Treatment with Immunosuppressive Agents (see the recommendations for children with IMN in the. Remuzzi G et al. Rituximab for idiopathic membranous nephropathy. Lancet. 2002;360(9337):923-4. Fervenza FC et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron. 2015;130(3):159-68 Fervenza FC1, Appel GB1, Barbour SJ1, Rovin BH1, Lafayette RA1, Aslam N1, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine . 2019 Jul 4. Figure 2 Guideline for the treatment of idiopathic membranous nephropathy. Patients can change from one category to another during the course of follow-up. Abbreviation is: ACEI, angiotensin-converting-enzyme inhibiting drug. *Supported by evidence from a controlled trial

Treatment of primary membranous nephropathy: where are we

Remuzzi G et al. Rituximab for idiopathic membranous nephropathy. Lancet. 2002;360(9337):923-4. Fervenza FC et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron. 2015;130(3):159-68 Treatment of secondary membranous nephropathy admin 2020-07-08T05:38:01+00:00 View Fullscreen CARI guidelines is proudly supported by Australia New Zealand Society of Nephrology, Kidney Health Australia and the NHMRC Program Grant - BEAT-CKD What is membranous nephropathy? Many diseases can affect your kidney function by attacking and damaging the glomeruli, the tiny filtering units inside your kidney where blood is cleaned. Glomerular diseases include many conditions with many different genetic and environmental causes. Membranous nephropathy (MN) is a type of glomerular disease and is an autoimmune disease is used to treat a kidney disease called membranous nephropathy. The Ponticelli regimen is named after Professor Claudio Ponticelli, an Italian doctor, who first demonstrated that it was effective in treating some people with membranous nephropathy. It is a 6 month treatment to dampen (or lower) your immune system Membranous nephropathy is an immune-mediated disease and is the leading cause of nephrotic syndrome in adults. Here, the authors discuss the role of B cell-depleting regimens in the treatment of.

UpToDat

  1. Clinician Information Membranous Nephropathy (MN) can only be definitively diagnosed by kidney biopsy but the recent availability of a blood test for specific autoantibodies, anti-PLA2R (phospholipase A2 receptor) and anti-THSD7A (anti-thrombospondin 1 containing 7A), holds promise for non-invasive diagnosis and monitoring of primary MN (autoimmune MN) in the future
  2. Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment. In adults, membranous nephropathy (MN) is a major cause of nephrotic syndrome. However, the etiology of approximately 75% of MN cases is idiopathic. Secondary causes of MN are autoimmune diseases, infection, drugs, and malignancy
  3. Overview. Membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids.[7619] When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood.
Nephropathy: Membranous Nephropathy Stages

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal Related articles in PubMed Yoga therapy for Obsessive Compulsive Disorder (OCD): A case series from India The KDIGO guideline provides guidance for the treatment of membranous nephropathy but several areas of uncertainty remain. (1) Better tools for predicting risk of disease progression are required 40 patients with idiopathic membranous glomerulonephritis were randomized to receive either no treatment or a regime of cyclophosphamide for 6 months, and warfarin and dipyridamole for two years Treatment of idiopathic membranous nephropathy has been controversial for decades. 1 Uncertainty mainly surrounds optimum therapeutic strategies for patients with nephrotic syndrome, because those with non-nephrotic proteinuria generally have a good outlook, independent of therapy. 2 Early retrospective studies suggested that glucocorticoids or.

Grand round- SLE- LUPUS NEPHRITIS

Management of Membranous Nephropathy after MENTOR

  1. Immunosuppressive treatment of patients with idiopathic membranous nephropathy (iMN) is heavily debated. The controversy is mainly related to the toxicity of the therapy and the variable natural course of the disease - spontaneous remission occurs in 40-50% of patients
  2. IgA nephropathy (IgAN) is a common glomerular disease, with mesangial-cell proliferation as a major feature. There is no disease-specific treatment. Platelet-derived growth factor (PDGF) contributes to the pathogenesis of IgAN. To better understand its pathogenic mechanisms, we assessed PDGF-mediated AXL phosphorylation in human mesangial cells and kidney-tissue biopsy specimens
  3. Membranous nephropathy is caused by the thickening of a part of the glomerular basement membrane. The glomerular basement membrane is a part of the kidneys that helps filter waste and extra fluid from the blood. The exact reason for this thickening is not known. The thickened glomerular membrane does not work normally
  4. Aims of the Group. 1. To develop evidence based clinical care pathways. Current treatment for Membranous Nephropathy (MN) is based on knowledge and drugs available in the 1990's. We are keen to support the development of new evidenced based therapy to improve outcomes for patients. 2

Membranous nephropathy: Treatment and prognosis - UpToDat

Treatment recommended for ALL patients in selected patient group. One third of patients have membranous nephropathy as a result of an underlying condition such as SLE, Sjogren syndrome, hepatitis B or C, or malignancy (commonly lung or colorectal). Treatment of any underlying cause usually resolves symptoms cost-efficacy) national and international guidelines recommended treatment with cyclophosphamide and steroids for patients with membranous nephropathy, nephrotic syndrome and high risk for disease progression (5). Many physicians and patients are reluctant to use cyclophosphamide and steroids, because of the associated toxicity Glomerulonephritis (GN) Recurrence. GN recurrence accounts for a large amount of kidney graft recipients evolving to end stage kidney disease. Its exact proportion varies from 3 to 18% of graft losses according to the series (55, 56) but probably, GN recurrence is under diagnosed in transplant recipients ().There are four main entities that explain the majority of cases of GN recurrence: focal. Primary membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome (NS) in adults [].The aims of therapy in primary MN have mainly focused on the prevention of end-stage renal disease (ESRD), which usually occurs after several years, whereas other complications of primary MN may occur much earlier in the course of the disease [] The discovery of circulating antibodies specific for native podocyte antigens has transformed the diagnostic workup and greatly improved management of idiopathic membranous nephropathy (iMN). In addition, their identification has clearly characterized iMN as a largely autoimmune disorder. Anti-PLA2R1 antibodies are detected in approximately 70% to 80% and anti-THSD7A antibodies in.

Membranous nephropathy (MN) is an immune complex-mediated cause of the nephrotic syndrome that can occur in all age groups, from infants to the very elderly. However, nephrotic syndrome in children is more frequently caused by conditions such as minimal change disease or focal segmental glomerulosclerosis, and much less commonly by MN. While systemic conditions such as lupus or infections such. Initial therapy for patients with membranous nephropathy is supportive 7; immunosuppressive therapy is recommended for patients with persistent nephrotic syndrome. 7,8 A regimen of alternating. Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in non-diabetic Caucasian adults over 40 years of age. It has an estimated incidence of 8-10 cases per 1 million. Fifty per cent of patients diagnosed with primary MN continue to have nephrotic syndrome and 30% of patients may progress to end-stage renal disease over 10 years. Although it was recognised as a distinct. Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, has been shown to be an effective therapy in treatment of patients with MN.

Lupus Nephritis | Teaching Point | Arkana Laboratories

KDIGO guidelines have been now published on glomerular diseases in KI this year. (image source: kidneypathology.com) Topic: Membranous Nephropathy. 1. Initial therapy should only be started on patients with nephrotic syndrome and one of the following: more than 4g/day of proteinuria AND remains over 50% of the baseline value, AND does not show. Recently, patients with membranous nephropathy at high risk for progressive disease experienced long-term proteinuria remission from treatment with RTX. [7] We report on an EXT1-associated MN patient who went into complete remission by therapy with low-dose RTX and has remained in remission during a follow-up of 16 months

Focal Segmental Glomerulosclerosis (FSGS)

promising horizons in the treatment of membranous glomerulonephritis. RTX could become a mainstay in the treatment of membranous glomerulonephritis due to its efficacy, safety profile and superiority to maintain clinical remission in the long term. The delayed response on proteinuria by RTX may be overcomed by the simultaneous use of CNIs Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life. Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys The guideline contains chapters on various glomerular diseases: steroid-sensitive nephrotic syndrome in children; steroid-resistant nephrotic syndrome in children; minimal-change disease; idiopathic focal segmental glomerulosclerosis; idiopathic membranous nephropathy; membranoproliferative glomerulonephritis; infection-related. membranous nephropathy is a glomerulonephritis characterized by subepithelial immune deposits containing antigen, immunoglobulin G (IgG), and complement components with little to no cellular proliferation or infiltration 1; common cause of adult-onset nephrotic syndrome (protein > 3 g/24 hour, edema, hypoalbuminemia, and hyperlipidemia)

Membranous nephropathy - Diagnosis and treatment - Mayo Clini

Membranous lupus nephritis (MLN) has a favorable prognosis compared to proliferative lupus nephritis (PLN) or combined MLN/PLN, although a significant proportion of cases will progress to end-stage kidney disease. There is considerable morbidity associated with thrombotic complications and treatment. Nondirected care includes renin-angiotensin-aldosterone system blockade, cardiovascular risk. Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome in adults. Recent figures from the Netherlands show an incidence in that country of around 10 per million population per year. 1 Identical clinical presentation and histological appearances can occur whether the condition is primary or idiopathic (IMN), or when it is secondary to various drugs, infections or. membranous nephropathy in adults in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be o Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in Caucasian adults. Considering the incidence of the glomerulopathies in Italy, MN is relatively frequent, representing 44.1% of patients diagnosed with nephrotic syndrome [].Initial studies performed in rat models (Heymann's nephritis) documented that subepithelial immune deposits were formed in situ in the basal.

Background . Membranous nephropathy (MN) can be associated with malignancy. However, the relative risk for malignancy remains unclear. It has been reported that higher numbers of inflammatory cells seen in the glomeruli at biopsy correlate with the occurrence of malignancy in patients with MN and might be used to direct screening. Methods glomerular disease Learn with flashcards, games, and more — for free Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and massive proteinuria. MN is the most common cause of nephrotic syndrome in adults leading to severe thrombotic complications and kidney failure

Qing HOU | Research Assistant | Nephrology

The discovery of anti-podocyte antibodies in primary membranous nephropathy (MN) has revolutionized our approach toward the diagnosis and treatment of this disease. Evaluation of serum levels of anti-podocyte antibodies paved the way for non-invasive diagnosis and helped distinguish between primary and secondary MN although the relationship between anti-podocyte antibodies and cancer remains. Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in the Caucasian adult population with an estimated incidence of 8-10 cases per 1 million and commonly seen in males above the age of 40. It is an immune-mediated disease that is pathologically characterized by thickening of the glomerular basement membrane and granular subepithelial deposits of immunoglobulins (Ig.

Lupus Nephritis Flashcards | Quizlet

Primary Membranous Nephropathy American Society of

  1. In a recently published STARMEN trial which randomized 86 pts with membranous nephropathy at high risk or progression to either cyclical alternating treatment with corticosteroids and cyclophosphamide or tacrolimus followed by single dose of rituximab complete or partial remission of nephrotic syndrome at 24 months was reached in 83.7% of.
  2. Introduction. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis recommend that patients with membranous nephropathy (MN) at risk for progression receive immunosuppressive therapy (IST), usually after 6 months of observation
  3. kdigo glomerulonephritis guidelines 2020. KDIGO clinical practice guideline for glomerulonephritis. More than 500,000 people in the United States live with end-stage renal disease (ESRD). Glomerulonephritis (GN) is a group of kidney diseases which while relatively rare, represent the second most common cause of end-stage renal disease in Canada
  4. Subjects with known diabetic nephropathy or nephrotic syndrome due to a disease or process other than idiopathic membranous nephropathy, or; Subjects requiring diagnostic or interventional procedure requiring a contrast agent must delay screening/randomization for at least 7 days. History of Systemic Lupus Erythematosus

The goal of membranous nephropathy treatment is to reduce symptoms and slow the progression of the disease. Controlling blood pressure is the most important way to delay kidney damage. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are the medicines most often used to lower blood pressure Meng et al. reported the successful treatment of HIV-associated membranous nephropathy treated with a modified Ponticelli regimen, though PLA2R testing was not performed. Most case reports of MN in the context of HIV focus on the initiation of ART [ 24 ], though, one saw a profound response to glucocorticoid therapy alone [ 25 ] Introduction. Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. The usual clinical presentation is a full nephrotic syndrome with preserved kidney function ().Considering that about a third of patients undergo spontaneous remission and a third progress to ESKD, the optimal management of MN is still a matter of debate (2 ⇓ ⇓ ⇓ ⇓ ⇓ -8)

[Application of guidelines in clinical practice: a

Membranoproliferative Glomerulonephritis (MPGN) is a specific type of glomerular disease that occurs when the body's immune system functions abnormally. The immune system, which is responsible for fighting disease, begins to attack healthy cells in the kidney, destroying the function of the filtering units of the kidney Membranous nephropathy is a common cause of nephrotic syndrome in adults and can be primary or secondary through autoimmune disease, medication, infection, or malignancy. Rapidly progressive glomerulonephritis with crescent formation is rare in patients with membranous nephropathy Membranous nephropathy is the most common cause of primary nephrotic syndrome in adults, most often presenting in the fifth and sixth decades. It is an immune-mediated disease characterized by immune complex deposition in the subepithelial portion of glomerular capillary walls Membranous nephropathy (MN) is one of the most common and challenging causes of nephrotic syndrome among adults. 1,2 Peak incidence occurs in the fourth and fifth decades of life, and overall incidence in adults is estimated at 1.2 per 100,000 per year. 3,4 Approximately 75% of MN cases are idiopathic membranous nephropathy (iMN), while secondary causes include autoimmune diseases, infection. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. vol. 9. 2009. pp. 2800-2807

Evaluating tacrolimus treatment in idiopathic membranous

Abstract: Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the forma- tion of electron-dense immune complexes, activation of complement and massive proteinuria Membranous nephropathy (MN) is a common glomerulopathy, especially in western countries where it accounts for more than one third of patients with nephrotic syndrome. MN is characterized by subepithelial deposition of podocyte targeted IgG4 antibodies What is membranoproliferative glomerulonephritis? Many diseases can affect your kidney function by attacking and damaging the glomeruli, the tiny filtering units inside your kidney where blood is cleaned. The conditions that affect your glomeruli are called glomerular diseases. Glomerular diseases include many conditions with many different causes Abstract The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis shed light on the complex world of glomerulonephritis therapy. However, they may no longer apply to idiopathic membranous nephropathy, as recently concluded by the KDIGO 2019 Working Group. This is due to the discovery of autoantibodies such as anti-phospholipase A2 receptor.

Membranous nephropathy - Symptoms, diagnosis and treatment

Pharmacological treatment of primary membranous nephropathy in 2016 Anne-Els van de Logt, Julia M. Hofstra and Jack F. Wetzels Radboud Institute for Health Sciences, Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands ABSTRACT Introduction: Therapy in patients with primary membranous nephropathy is debated Membranous nephropathy (MN) is an immune complex-mediated cause of the nephrotic syndrome that can occur in all age groups, from infants to the very elderly. However, nephrotic syndrome in children is more frequently caused by conditions such as minimal change disease or focal segmental glomerulosclerosis, and much less commonly by MN. While systemic conditions such as lupus or infections such.

Rituximab in Membranous Nephropath

Treatment of secondary membranous nephropathy Treatment of secondary membranous nephropathy Thomas, Merlin 2006-04-01 00:00:00 GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence) • Removal of underlying causes of membranous glomerulonephritis (MGN) has been associated with clinical remission. Membranous nephropathy is also called membranous glomerulonephritis. Glomerulonephritis means inflammation of the filters of the kidney (which are called glomeruli). Nephropathy means a disease of the kidneys. In membranous nephropathy, damage to the kidney's filters allows protein in the blood circulating through the kidneys to leak into. Treatment for glomerulonephritis depends on the cause of your condition and your symptoms. In mild cases, treatment is not always necessary. If treatment is needed, it's usually carried out by a kidney specialist. Dietary changes. In mild cases, a GP or dietitian will give you relevant advice about diet. You may be advised to reduce your intake of Clinical Practice Guideline for Glomerulonephritis provides guidance for the treatment of idiopathic membranous nephropathy. The guideline suggests that immunosuppressive therapy should be restricted to patients with nephrotic syndrome and persistent proteinuria, deteriorating kidney function or severe symptoms

The KDIGO guideline for glomerulonephritis is designed to assist health-care providers in treating patients with glomerularGlomerulonephritis / therapy* * Glomerulonephritis, IGA / therapy * Glomerulonephritis, Membranous / therapy * The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Treatment decisions often follow formal or informal algorithmic guidelines. Treatment options can often be ranked or prioritized into lines of therapy: first-line therapy, second-line therapy, third-line therapy, and so on. Membranous nephropathy (MN) is a kidney disease that affects the filters (glomeruli) of the kidney and can cause. Original Research Articles Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi:1 Membranous Nephropathy - InTech. Primary membranous nephropathy (IMN). MN can be secondary to a wide spectrum of infections, tumors, autoimmune diseases or exposure to drugs or toxic agents. The treatment of membranous nephropathy in patients with normal renal function remains.

Glomerulonephritis is often part of a multisystem disorder. Edema is a sign of severe or chronic disease. A renal biopsy is the test for definitive diagnosis, although it is not required in all patients. Treating the underlying disorder and managing hypertension, hyperlipidemia, and proteinuria i.. KDIGO 2012 guidelines did not consider rituximab as a possible treatment for primary membranous nephropathy .6 In July 2019, the MENTOR study — MEmbranous Nephropathy Trial Of Rituximab — on the remission of proteinuria in 130 patients with primary membranous nephropathy was published. Trial Under Revie 4. Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. 5. Has a low potential for abuse relative to those in schedule 4 nephropathy in 2016' [1]. Membranous nephropathy (MN) is an immune complex-mediated cause of nephrotic syndrome that may occur in all age groups, but shows low prevalence in the pediatric population [2]. Therefore, there are very limited studies that present data regarding the optimal treatment and no stan-dardized pharmacological treatment. Schieppati A, Perna A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. The Cochrane Database 2004 of Systematic Reviews, Issue 4. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-9

Background: This study aims to assess whether immunosuppression is beneficial in the treatment of idiopathic membranous nephropathy (IMN). Methods: We reviewed randomized controlled trials (RCTs) addressing the effect of immunosuppression on histologically proven IMN in adults with nephrotic syndrome followed up for at least 6 months Background Immunosuppressive agents in general are shown to prevent renal progression and all-cause mortality in idiopathic membranous nephropathy (IMN) patients with nephrotic syndrome. However, the efficacy and safety of different immunosuppressive treatments have not been systematic assessed and compared. A network meta-analysis was performed to compare different immunosuppressive treatment. Introduction Primary membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. The disease may have different long-term outcomes. After 10 years of follow-up, 35%-50% of the untreated patients with persistent nephrotic syndrome may die or progress to end stage renal disease. The 2012 KDIGO (Kidney Disease Improving Global Outcomes) guidelines recommend that initial. In our glomerulonephritis cases, membranous nephropathy, granulomatous with C3 glomerular deposition, and focal segmental glomerulosclerosis, and one of the 2 cases of CPI-related IgA nephropathy had complete or partial recovery after starting prednisone (0.5 mg/kg-3 mg/kg)